SEC Filing Summary: Collegium Pharmaceutical, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Collegium Pharmaceutical, Inc. on May 10, 2022. The report serves as a current notification regarding the company's financial results for the quarterly period ended March 31, 2022. The company is incorporated in Virginia and trades on the NASDAQ Global Select Market under the symbol "COLL."
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This 8-K acts as a reference document, stating that the detailed financial results are contained in a press release (Exhibit 99.1) and an earnings presentation (Exhibit 99.2) which are furnished but not filed within the body of this report.
Material Changes
No material changes or comparative financial data are disclosed within the text of this filing. The document solely announces the issuance of the Q1 2022 results and the accompanying presentation.
Guidance, Outlook, and Risks
The filing references an earnings presentation (Exhibit 99.2) which typically contains management commentary, guidance, and outlook, but the specific content of these sections is not included in the provided text. No specific risks, contingencies, or unusual items are detailed in this summary document.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2022 revenue, net loss, and cash position figures.
- Examine Exhibit 99.2 (Earnings Presentation) for updated clinical trial timelines, regulatory milestones, and forward-looking guidance.
- Verify the company's cash runway and burn rate as disclosed in the attached exhibits.
- Check for any updates on the status of the company's lead drug candidates mentioned in the presentation.